As men age, the prostate gland can enlarge to benign hyperplasia. Enlargement of the prostate can constrict the urethra, which can reduce urinary flow rates and cause urinary hesitancy, urgency, increased frequency, dysuria, and urinary tract infection. In addition to the mechanical component caused by the physically This study was carried out to obtain information on the efficacy and safety of the controlled release formulation of the doxazosin Gastrointestinal Therapeutic System (GITS) in Taiwanese subjects with benign prostatic hyperplasia (BPH). Studies of doxazosin in Asian populations for this indication have lacked data particularly from Taiwan. This was an 8-week, post-marketing, open-label, noncomparative study. Eighty male subjects (mean age = 64 years) with BPH received doxazosin GITS 4 mg once daily. At week 4, subjects who achieved an increase in maximum urinary flow rate (Qmax) of ≥ 3 mL/s and a ≥ 30% reduction in the total International Prostate Symptom Score (IPSS) continued on doxazosin GITS 4 mg for the remaining 4 weeks; all other subjects were up-titrated to 8 mg once daily. Change from baseline at weeks 4 and 8 (primary endpoint) in IPSS and Qmax was evaluated using two-sided paired t tests for the intent-to-treat population. Safety was assessed throughout the study. A total of 53 (66.3%) subjects completed the study. Baseline Qmax and IPSS were 10.7 ± 3.4 mL/s and 20.6 ± 5.4, respectively. At week 8, a significant increase from baseline in Qmax of 3.3 ± 4.6 mL/s (95% confidence interval = 2.2-4.4, p < 0.001) and a significant decrease in total IPSS of -8.9 ± 7.0 (95% confidence interval = -10.5 to -7.3, p < 0.001) was observed. The most common treatmentrelated adverse event was dizziness. Doxazosin GITS 4 mg per day (with an 8-mg titration step) effectively improved symptoms of BPH. The results from this study provide further information for clinicians on the use of doxazosin GITS for the treatment of BPH, particularly in Taiwanese patients.
enlarged prostate, a dynamic component caused by variations in the tone of the prostate smooth muscle contributes to the obstruction. This tone is controlled by the α-1 adrenergic receptors of the sympathetic nervous system. Selective α-1 inhibitors, such as doxazosin, have been shown in several clinical trials to improve urinary function and clinical symptoms of subjects with benign prostate hyperplasia (BPH) [1, 2] .
The doxazosin Gastrointestinal Therapeutic System (GITS) is a controlled release formulation. It has been developed to produce a peak plasma concentration with no higher than the 1-mg dose of immediaterelease doxazosin, while achieving greater overall systemic exposure. Moreover, curative levels can be achieved more rapidly with this formulation without the addition of excessive titration steps [3] . Doxazosin GITS has demonstrated efficacy, particularly for improvement of symptom scores and increase in maximum urinary flow (Qmax), as well as demonstrating benefits on quality of life (QoL) [4, 5] . The efficacy and tolerability of 4-mg and 8-mg single doses of doxazosin GITS have been compared with a single dose of 1 mg immediate release doxazosin in subjects with mild-to-moderate hypertension, which results in similar outcomes [2] .
The prevalence of BPH is difficult to determine because a standardized definition is lacking; however, the manifestation of lower urinary tract symptoms is widely accepted [6, 7] . Some clinical estimates of BPH prevalence range from 80% in subjects aged > 80 years in the United States [8] to 63% in those aged > 70 years in an Asian population [9] . Surgical therapy has been associated with higher treatment failure rates, coupled with greater costs over the long term, therefore, effective and tolerable medical treatment is highly sought [10, 11] .
Although data are available on doxazosin GITS for the treatment of BPH in many western populations, there remain limited data in Asian populations, particularly in Taiwan. This study was designed to evaluate the safety and efficacy of doxazosin GITS in Taiwanese subjects with BPH.
METHODS

Study design
This was a post-marketing open-label study conducted at five centers in Taiwan. Subjects were required to attend the center on three occasions: baseline, week 4, and week 8. All subjects were initiated on doxazosin GITS 4 mg once daily to be taken at breakfast. At week 4, an efficacy response-based dose titration occurred: subjects who achieved an increase in Qmax of ≥ 3 mL/s and a ≥ 30% reduction in the total International Prostate Symptom Score (IPSS) from baseline continued on doxazosin GITS 4 mg for the remainder of the study; all other subjects were up-titrated to doxazosin GITS 8 mg once daily for the remainder of the study. The 8-week duration was chosen because previous studies have shown that most changes in total IPSS and Qmax are rapid and occur within the initial 8 weeks of doxazosin GITS treatment [12] .
Inclusion and exclusion criteria
This study was conducted in accordance with the latest version of the Declaration of Helsinki in 2008. The protocol (study code: A0351063) was approved by the Institutional Review Board at each center and written informed consent was obtained from each subject as a condition of entry.
We enrolled Taiwanese male subjects aged 50-80 years with a primary diagnosis of BPH, which was defined an enlarged prostate (confirmed by digital rectal examination and/or B-mode ultrasound), a baseline IPSS score ≥ 12, and a baseline Qmax of 5-15 mL/s in a total voided volume ≥ 150 mL. Subjects who had previous prostate surgery or those who had a stent, microwave thermotherapy, and/or balloon dilation within the previous 6 months were excluded. Individuals who presented with known or suspected prostate malignancy, or prostate specific antigen (PSA) levels > 10 ng/mL, were also excluded.
Measurements
Efficacy was assessed using a subject-completed IPSS questionnaire and Qmax at baseline, week 4, and week 8 (primary evaluations). The IPSS questionnaire comprised of two components: symptom score and QoL. At each visit, Qmax was determined using a urinary flow meter. Other efficacy assessments included postvoid residual urine volume, as determined by B-mode ultrasound at each visit. The efficacy response was classified as the proportion of subjects who achieved an increase in Qmax of ≥ 3 mL/s and a ≥ 30% reduction in total IPSS score. Safety assessment included adverse events, treatment discontinuation, clinical laboratory tests, and physical examination at baseline and week 8.
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Vital signs (sitting blood pressure and heart rate) were measured at each visit.
Statistical analysis
Sample size calculations were based on a significance level of 2.5% to ensure that the overall type I error did not exceed 5% for both of the primary endpoints. Assuming a 20% attrition rate, a sample size of 80 subjects would provide 95% power to detect a difference from baseline of four units in the total IPSS [standard deviation (SD): 8 units), and 85% power to detect a difference from baseline of 3 mL/s (SD: 7 mL/s) in Qmax.
The intent-to-treat (ITT) population (subjects who took at least one dose of study medication and provided at least one post-baseline efficacy measure) and the per-protocol population (ITT subjects without major protocol violations who were compliant with taking study medication, and had both primary endpoints measured at day 26 or thereafter) were used to test the primary efficacy endpoints. Evaluation of the mean change from baseline to the end of the study (week 8) was conducted on total IPSS and Qmax using two-sided paired t tests at the 2.5% significance level. Secondary efficacy endpoints were analyzed using paired t tests for the ITT population. If a subject withdrew, the last available post-baseline observation was carried forward and used in the analyses at weeks 4 and 8. Mean change, ± SD or p values and 95% confidence intervals (CIs) are presented.
Standard summaries of safety parameters as defined by the sponsor's worldwide safety standards were generated for the safety population (i.e. all subjects who took at least one dose of study medication). Compliance was assessed at each visit by calculating the ratio between the total dosage taken and the total dosage that should have been taken during follow-up. Non-compliance was defined as taking < 80% or > 120% of study treatment.
RESULTS
Participants
A total of 90 male Asian subjects from five centers were screened: 80 (100%) were treated with doxazosin GITS, and 53 (66.3%) completed the study. Subject disposition is presented in the Figure. The mean age was 64 years (range, 49-84 years), and the mean duration of BPH at baseline was 2.2 years (range, 0-11.9 years). The mean baseline PSA level was 2.3 ± 2.5 ng/mL. Hypertension (n = 16, 20.0%), diabetes (n = 9, 11.3%), and urethra and urinary tract disorders (n = 8, 10.0%) were the most common disorders present at baseline. Concomitant medications were taken by 47 (58.8%) subjects; the most common of which were antacids (16%), anti-inflammatory analgesics (15%), calcium channel blockers (11%), and oral antidiabetic drugs (11%).
Study treatment
The median duration of treatment was 53 days (range, 1-62 days). Thirty (38%) subjects were uptitrated to doxazosin GITS 8 mg at week 4, and 24 (30%) remained on doxazosin GITS 4 mg. The compliance (80-120%) to study treatment at each visit was high (94-98%), and the overall mean compliance was 95 ± 15.3%.
IPSS
The absolute mean baseline total IPSS for the ITT population was 20.6 ± 5.4. Doxazosin GITS significantly improved (decreased) the total IPSS from baseline to week 8 by −8.9 ± 7.0 (p < 0.001, 95% CI = 10.5 to −7.3). Furthermore, this improvement was evident as early as week 4 ( Table 1) . A similar improvement was observed for the per protocol analysis population at week 8: change from baseline to −10.6 ± 6.4 (p < 0.001; 95% CI = −12.4 to −8.8).
Qmax
Statistically significant mean increases from baseline in Qmax were observed at week 8 following treatment with doxazosin GITS for the ITT and per protocol populations. Table 2 presents the baseline absolute mean and week 4 and 8 changes from baseline for both population groups. The majority of increases in Qmax occurred by week 4: change from baseline was 3.2 ± 4.7 mL/s (p < 0.001).
Urine volume
The change in post-void residual volume did not reach statistical significance at any time point, although it decreased (improved) from a mean baseline value of 40.3 ± 53.3 mL at week 4 by 9.4 ± 51.7 mL and at week 8 by 9.3 ± 49.5 mL.
QoL
Doxazosin GITS produced a significant decrease (improvement) in QoL score at weeks 4 and 8. The mean baseline QoL index score was 4.1 ± 1.1. A mean change from baseline to week 4 of −1.1 ± 1.4 (p < 0.001; 95% CI = −1.4 to −0.8) was observed. This improvement 
Responders
The proportion of subjects who achieved a ≥ 3 mL/s increase in Qmax and a ≥ 30% reduction in total IPSS from baseline at weeks 4 and 8 was 34% and 43%, respectively. A greater proportion of subjects on doxazosin GITS achieved a ≥ 30% reduction in total IPSS from baseline at weeks 4 (64%) and 8 (67%) than subjects who achieved a ≥ 3 mL/s increase in Qmax at weeks 4 (41%) and 8 (51%).
Safety
A total of 49 adverse events were reported in 33 (41.3%) subjects, and 35 adverse events reported in 23 (28.8%) subjects were considered to be treatment-related. The most commonly reported treatment-related adverse event was dizziness (n = 12, 15.0%). Other treatmentrelated events had a frequency of ≤ 5%; the most frequent of which were chest pain, pruritus, dry mouth, and peripheral edema (all of which had a frequency of ≥ 2%). Ten (12.5%) subjects permanently discontinued treatment due to related adverse events; all subjects were on doxazosin GITS 4 mg at the time of discontinuation. Eight (10.0%) subjects discontinued due to dizziness, which might have been experienced alone or in combination with other adverse events. Only two treatment-related adverse events were reported as severe: dizziness and sexual dysfunction. One (1.3%) subject experienced acute pancreatitis and exacerbation of gouty arthritis, both of which were reported as serious adverse events that were not related to study treatment; the subject recovered and remained in the study.
DISCUSSION
The aim of this study was to evaluate the efficacy and safety of doxazosin GITS 4 mg per day (with an 8 mg/ day titration step) in a Taiwanese population with BPH. The results showed significantly marked improvements from baseline for the primary efficacy endpoints and a number of the secondary efficacy endpoints. In addition, benefits in QoL and a favorable safety profile were observed.
The total IPSS was significantly improved from baseline by -8.9 with doxazosin GITS at week 8. IPSS is a validated tool for assessing symptom frequency and severity, and is widely recognized as the international standard [7] . Doxazosin GITS decreased the mean baseline total IPSS from a classification of severe (20.6; severe 20-35) to moderate (11.7; moderate 8-19) , as determined by the American Urological Association [13] , within 8 weeks. Furthermore, this result was observed as early as week 4. The results of this study are comparable to those published from other studies of doxazosin GITS in western populations in which total IPSS improvements of -8.1 [1] and -8.0 [14] have been reported. It is worth noting that the IPSS improvements shown in these western populations were observed after 13 weeks of treatment. However, a comparable improvement was observed after only 4 weeks in our Taiwanese population.
The proportion of subjects who achieved a ≥ 3 mL/s increase in Qmax and a ≥ 30% reduction in total IPSS (responders) from baseline at weeks 4 and 8 was 34% and 43%, respectively. These results are similar to those observed by Kirby et al, who documented that 32% of subjects achieved both of these endpoints at week 13 [2] . A greater proportion of subjects achieved a ≥ 30% reduction in total IPSS from baseline at weeks 4 (64%) and 8 (67%) than subjects who achieved a ≥ 3 mL/s increase in Qmax at weeks 4 (41%) and 8 (51%). Chung et al reported that 84% of subjects achieved a ≥ 30% reduction in IPSS from baseline at week 12 with doxazosin 2, 4 or 8 mg per day [15] . The higher figure is probably explained by the longer duration of treatment compared with the present study. Doxazosin GITS has demonstrated efficacy for up to 13 weeks, and further investigation is required to establish its efficacy in the longer term.
Further to the improvements in efficacy measures, doxazosin GITS also demonstrated benefits in QoL as measured by the IPSS questionnaire. The change from baseline in QoL after 2 months of treatment with doxazosin GITS was -1.3, which is comparable with the 3-9-month QoL results (change from baseline, -1.25) presented for doxazosin in a recent review of all α-blockers [16] . As prevalence of BPH is increasing as a result of an aging population, agents that improve symptoms as well as QoL are increasingly important.
Individuals with BPH commonly report higher levels of PSA, possibly due to the disruption and change in volume of the prostate. The Medical Therapy of the Prostatic Symptoms (MTOPS) trial observed that baseline PSA level in the doxazosin treatment group (mean baseline PSA = 2.4 ng/mL) was a predictor of risk of clinical progression of BPH and invasive therapy [17] . Subjects in this study had a mean baseline PSA level of 2.3 ng/mL, which is similar to that in previous studies.
In the current study, we observed a favorable safety profile with doxazosin 4 and 8 mg per day. The most common adverse event was dizziness, which was also the most frequent reason for treatment discontinuation. Dizziness is known to occur with α-blockers, although differences in frequency have been shown with different agents [16] . Dizziness has been reported previously with doxazosin use [18, 19] , therefore, this finding was not unexpected.
A few limitations must be noted for the present study. The study was designed as an open-label, noncomparative trial; however, the treatment effect observed was similar to findings reported for placebocontrolled studies. The present study had a relatively short duration of 8 weeks, and longer-term studies in this population are needed to establish a sustained benefit over time.
In summary, this multicenter, open-label study demonstrated that doxazosin GITS 4 mg per day (with an 8 mg/day titration step) effectively improved urinary flow and other symptoms of BPH in a Taiwanese population. Statistically significant improvements were observed in the majority of efficacy measures, as early as week 4, and maintained at week 8. Additionally, significant benefits were demonstrated in QoL, and doxazosin GITS was found to be safe and well-tolerated in this study population. These data will provide further information for clinicians on the use of doxazosin GITS for the treatment of BPH, particularly in Taiwanese patients.
